Stockscreener 앱 받기
1.23
0.79%
-0.03
시간 외 거래:
1.23
Pds Biotechnology Corporation 주식(PDSB)의 최신 뉴스
PDS Biotechnology at Life Sciences Virtual Investor Conference: Strategic Advances in Cancer Treatment - Investing.com India
PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer - Marketscreener.com
PDS Biotechnology Receives FDA Clearance for Versamune MUC1 Trial in Colon Cancer - Marketscreener.com
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer - The Manila Times
PDS Biotech Leadership to Participate in March Conferences - The Manila Times
PDS Biotechnology commences trial for head and neck squamous cell carcinoma - Yahoo
H.C. Wainwright maintains $21 target on PDS Biotech stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains $21 target on PDS Biotech stock - Investing.com India
HC Wainwright Reiterates “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB) - Defense World
PDS Biotech begins phase 3 trial for HPV cancer therapy By Investing.com - Investing.com Australia
PDS Biotech launches phase 3 trial for HPV cancer therapy By Investing.com - Investing.com Australia
PDS Biotech launches phase 3 trial for HPV cancer therapy - Investing.com India
PDS Biotech begins phase 3 trial for HPV cancer therapy - Investing.com India
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer - The Manila Times
Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors - The Globe and Mail
Understanding the Risks of Investing in PDS Biotechnology Corporation (PDSB) - Knox Daily
PDS Biotechnology’s Stephen Glover purchases $25,001 in common stock By Investing.com - Investing.com Canada
PDS Biotechnology director Gregory Freitag purchases $24,999 in stock By Investing.com - Investing.com Canada
PDS Biotechnology director Gregory Freitag purchases $24,999 in stock - Investing.com India
PDS Biotechnology’s Stephen Glover purchases $25,001 in common stock - Investing.com India
PDS Biotechnology Directors Increase Holdings with Recent Purchases - TradingView
PDSB stock touches 52-week low at $1.2 amid sharp annual decline By Investing.com - Investing.com South Africa
PDSB stock touches 52-week low at $1.2 amid sharp annual decline - Investing.com India
EMV Capital portfolio company PDS Biotechnology raises $11mln - Proactive Investors Australia
PDS Biotechnology Launches Registered Direct Offering; Shares Up -February 27, 2025 at 12:02 pm EST - Marketscreener.com
PDS Biotechnology Corp. to Host Earnings Call - ACCESS Newswire
PDS Biotech secures $11 million in direct offering By Investing.com - Investing.com South Africa
PDS Biotech secures $11 million in direct offering - Investing.com India
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology - The Manila Times
Where Do Analysts Think The PDS Biotechnology Corporation (NASDAQ: PDSB) Is Going - Stocks Register
PDS Biotechnology (NASDAQ:PDSB) Given Buy Rating at HC Wainwright - Defense World
PDS Biotech stock plunges to 52-week low of $1.25 By Investing.com - Investing.com Nigeria
Do you want to know where to find good stock? Take a look at PDS Biotechnology Corporation’s (NASDAQ:PDSB) Sentiment Analysis – US Post News - US Post News
PDS Biotech stock plunges to 52-week low of $1.25 - Investing.com
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research - The Manila Times
PDS Biotechnology Reports Promising Phase 2 Results for Versamune® HPV in Treating HPV16-Positive Cancers; Phase 3 Trial Planned for Q1 2025 - Nasdaq
Cancer Breakthrough? PDS Biotech's HPV Treatment Shows Perfect Survival Rate in Latest Trial - StockTitan
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025 - The Manila Times
Can PDS Biotech's Latest Oncology Developments Transform Cancer Treatment? CEO to Reveal Strategy - StockTitan
PDSB stock touches 52-week low at $1.3 amid market challenges - MSN
Cancer Vaccines Market on Track for Major Expansion in the - GlobeNewswire
Cancer Vaccines Market on Track for Major Expansion in - One News Page
PDSB stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa
PDS Biotechnology (NASDAQ:PDSB) Trading Down 5.8%What's Next? - MarketBeat
0.57%
자본화:
|
볼륨(24시간):